Following 1H results for Tissue Repair that were in-line with Morgans expectations (and no major news updates), the broker focuses upon the buying opportunity presented by a share price trading below cash backing. 

The cash balance of $26.6m (no debt) is sufficient to complete the clinical programs in chronic wounds as well as initial commercialisation of the aesthetic product, points out the analyst.

Target price is $1.43.Current Price is $0.43. Difference: $1.00 - (brackets indicate current price is over target). If TRP meets the Morgans target it will return approximately 70% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2022 Acquisdata Pty Ltd., source FN Arena